Strength in Numbers: EU Cross-Country Drug Pricing Coalitions Join Forces
Concerns Emerge Over Insufficient Data To Support Decision-Making
Two groups of smaller European countries have agreed to collaborate on tackling challenges relating to accessing expensive new medicines.
You may also be interested in...
Five Nordic countries are agreeing a common strategy for closer collaboration on access to hospital drugs.
Biogen/Eisai’s Alzheimer’s drug aducanumab could face difficulties with health technology appraisal institutes should it win approval in the EU.
The Dutch HTA institute is calling for hefty discounts of 50% and 75% for Novartis’s gene therapy and Vertex’s cystic fibrosis product.